Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 3, 2016
- Accepted for publication August 22, 2016
- Published online October 2, 2016.
Copyright & Usage
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Harshad R. Kulkarni1,
- Aviral Singh1,
- Christiane Schuchardt1,
- Karin Niepsch1,
- Manal Sayeg1,
- Yevgeniy Leshch2,
- Hans-Juergen Wester3 and
- Richard P. Baum1
- 1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
- 2Division of Radiopharmacy, Zentralklinik Bad Berka, Bad Berka, Germany; and
- 3Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technical University Munich, Munich, Germany
- For correspondence or reprints contact: Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, 99437 Bad Berka, Germany. E-mail: richard.baum{at}zentralklinik.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists
- Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
- Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
- Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
- Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
- 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer
- Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
- Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising {alpha}-Particle, {beta}--Particle, and Auger Electron Emitters
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer
- Effect of Androgen on Normal Biodistribution of [18F]-2-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice
- Radiotheranostics in Prostate Cancer: Introduction and Overview